These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 1346800)

  • 1. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
    Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
    J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
    J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
    Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
    Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.
    Krance RA; Hurwitz CA; Head DR; Raimondi SC; Behm FG; Crews KR; Srivastava DK; Mahmoud H; Roberts WM; Tong X; Blakley RL; Ribeiro RC
    J Clin Oncol; 2001 Jun; 19(11):2804-11. PubMed ID: 11387351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
    Piro LD; Carrera CJ; Carson DA; Beutler E
    N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
    Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
    Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
    Gordon MS; Young ML; Tallman MS; Cripe LD; Bennett JM; Paietta E; Longo W; Gerad H; Mazza J; Rowe JM
    Leuk Res; 2000 Oct; 24(10):871-5. PubMed ID: 10996206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
    Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
    Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B; Weisdorf DJ; Kim T; Kersey JH; Ramsay NK
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
    Estey EH; Kurzrock R; Kantarjian HM; O'Brien SM; McCredie KB; Beran M; Koller C; Keating MJ; Hirsch-Ginsberg C; Huh YO
    Blood; 1992 Feb; 79(4):882-7. PubMed ID: 1346577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.
    Santana VM; Hurwitz CA; Blakley RL; Crom WR; Luo X; Roberts WM; Ribeiro R; Mahmoud H; Krance RA
    Blood; 1994 Aug; 84(4):1237-42. PubMed ID: 7914104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.